+

WO2002053171A3 - Utilisation de canaux potassiques de conductance intermediaire et de modulateurs pour le diagnostic et le traitement d'affections a activite keratinocytaire perturbee - Google Patents

Utilisation de canaux potassiques de conductance intermediaire et de modulateurs pour le diagnostic et le traitement d'affections a activite keratinocytaire perturbee Download PDF

Info

Publication number
WO2002053171A3
WO2002053171A3 PCT/EP2001/015317 EP0115317W WO02053171A3 WO 2002053171 A3 WO2002053171 A3 WO 2002053171A3 EP 0115317 W EP0115317 W EP 0115317W WO 02053171 A3 WO02053171 A3 WO 02053171A3
Authority
WO
WIPO (PCT)
Prior art keywords
diagnosis
treatment
potassium channels
modulators
illnesses
Prior art date
Application number
PCT/EP2001/015317
Other languages
German (de)
English (en)
Other versions
WO2002053171A2 (fr
Inventor
Andreas Goppelt
Christian Alzheimer
Heidi Koegel
Original Assignee
Switch Biotech Ag
Univ Muenchen L Maximilians
Andreas Goppelt
Christian Alzheimer
Heidi Koegel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10065475A external-priority patent/DE10065475A1/de
Application filed by Switch Biotech Ag, Univ Muenchen L Maximilians, Andreas Goppelt, Christian Alzheimer, Heidi Koegel filed Critical Switch Biotech Ag
Priority to AT01272669T priority Critical patent/ATE291435T1/de
Priority to EP01272669A priority patent/EP1345618B1/fr
Priority to CA002433041A priority patent/CA2433041A1/fr
Priority to US10/451,805 priority patent/US20040248099A1/en
Priority to JP2002554120A priority patent/JP2004530642A/ja
Priority to DE50105735T priority patent/DE50105735D1/de
Publication of WO2002053171A2 publication Critical patent/WO2002053171A2/fr
Publication of WO2002053171A3 publication Critical patent/WO2002053171A3/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6881—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from skin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/20—Dermatological disorders
    • G01N2800/205—Scaling palpular diseases, e.g. psoriasis, pytiriasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Urology & Nephrology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pulmonology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne l'utilisation de canaux potassiques activés par le calcium de conductance intermédiaire ou d'acides nucléiques codant pour eux provenant de l'homme ou de la souris pour le diagnostic, la prévention ou le traitement d'affections liées à une activité kératinocytaire perturbée, ainsi que leur utilisation pour l'identification de principes actifs pharmacologiques. L'invention concerne également l'utilisation de modulateurs de canaux potassiques activés par le calcium de conductance intermédiaire pour le diagnostic, la prévention ou le traitement d'affections liées à une activité kératinocytaire perturbée.
PCT/EP2001/015317 2000-12-28 2001-12-27 Utilisation de canaux potassiques de conductance intermediaire et de modulateurs pour le diagnostic et le traitement d'affections a activite keratinocytaire perturbee WO2002053171A2 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
AT01272669T ATE291435T1 (de) 2000-12-28 2001-12-27 Chlorzoxazon zur behandlung von psoriasis
EP01272669A EP1345618B1 (fr) 2000-12-28 2001-12-27 Chlorzoxazone pour le traitement du psoriasis
CA002433041A CA2433041A1 (fr) 2000-12-28 2001-12-27 Utilisation de canaux potassiques de conductance intermediaire et de modulateurs pour le diagnostic et le traitement d'affections a activite keratinocytaire perturbee
US10/451,805 US20040248099A1 (en) 2000-12-28 2001-12-27 Use of intermediate -conductance potassium channels and modulators for diagnosing and treating diseases having disturbed keratinocyte activity
JP2002554120A JP2004530642A (ja) 2000-12-28 2001-12-27 障害のあるケラチノサイト活性に関係する疾患を診断および処置するための中コンダクタンス型カリウムチャネルおよびモジュレーターの使用
DE50105735T DE50105735D1 (de) 2000-12-28 2001-12-27 Chlorzoxazon zur behandlung von psoriasis

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE10065475.4 2000-12-28
DE10065475A DE10065475A1 (de) 2000-12-28 2000-12-28 Verwendung von "intermediate-conductance" Kaliumkanälen und Modulatoren zur Diagnose und Behandlung von Krankheiten mit gestörter Keratinozytenfunktion
US27745301P 2001-03-20 2001-03-20
US60/277,453 2001-03-20

Publications (2)

Publication Number Publication Date
WO2002053171A2 WO2002053171A2 (fr) 2002-07-11
WO2002053171A3 true WO2002053171A3 (fr) 2003-03-20

Family

ID=26008117

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2001/015317 WO2002053171A2 (fr) 2000-12-28 2001-12-27 Utilisation de canaux potassiques de conductance intermediaire et de modulateurs pour le diagnostic et le traitement d'affections a activite keratinocytaire perturbee

Country Status (5)

Country Link
EP (1) EP1345618B1 (fr)
JP (1) JP2004530642A (fr)
AT (1) ATE291435T1 (fr)
CA (1) CA2433041A1 (fr)
WO (1) WO2002053171A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10250870A1 (de) * 2002-10-31 2004-05-13 Switch Biotech Ag Zusammensetzung enthaltend Aktivatoren von IK-Kaliumkanälen und Calcineurin-Antagonisten und deren Verwendung
WO2004064835A1 (fr) * 2003-01-17 2004-08-05 Neurosearch A/S Utilisation d'agents de modulation du canal ionique pour traiter la douleur
US7851431B2 (en) * 2005-07-27 2010-12-14 Prescription Dispensing Laboratories Treatment of actinic keratoses with calcium channel blockers

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4569935A (en) * 1983-03-17 1986-02-11 University Of Tennessee Research Corp. Topical treatment of psoriasis with imidazole antibiotics
US4680296A (en) * 1984-10-16 1987-07-14 Synthelabo Piperidine derivatives and pharmaceutical compositions containing them
GB2273873A (en) * 1992-12-23 1994-07-06 Univ Sheffield Treatment of psoriasis
WO1997018332A1 (fr) * 1995-11-13 1997-05-22 Brandeis University Regulation des tyrosine-kinases cancerogenes par conductance en ions potassium
WO1998011139A1 (fr) * 1996-09-11 1998-03-19 Oregon Health Sciences University Canaux potassium a basse et moyenne conductance actives par le calcium et leurs utilisations
WO1999025347A2 (fr) * 1997-11-14 1999-05-27 Neurosearch A/S Composes chimiques ayant une activite de blocage des canaux ioniques et servant au traitement de troubles immunitaires
JPH11209302A (ja) * 1998-01-21 1999-08-03 Pola Chem Ind Inc 抗掻痒剤
WO2000034228A1 (fr) * 1998-12-04 2000-06-15 Neurosearch A/S Agents de modulation de canaux ioniques
WO2000033834A1 (fr) * 1998-12-04 2000-06-15 Neurosearch A/S Utilisation de derives d'isatine en tant qu'agents d'activation de canaux ioniques
WO2000034248A1 (fr) * 1998-12-04 2000-06-15 Neurosearch A/S Nouveaux derives de benzimidazolone, de benzoxazolone ou de benzothiazolone agissant comme agents de modulation de canaux ioniques
WO2000037422A2 (fr) * 1998-12-22 2000-06-29 Neurosearch A/S Agents de modulation de canaux ioniques

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4569935A (en) * 1983-03-17 1986-02-11 University Of Tennessee Research Corp. Topical treatment of psoriasis with imidazole antibiotics
US4680296A (en) * 1984-10-16 1987-07-14 Synthelabo Piperidine derivatives and pharmaceutical compositions containing them
GB2273873A (en) * 1992-12-23 1994-07-06 Univ Sheffield Treatment of psoriasis
WO1997018332A1 (fr) * 1995-11-13 1997-05-22 Brandeis University Regulation des tyrosine-kinases cancerogenes par conductance en ions potassium
WO1998011139A1 (fr) * 1996-09-11 1998-03-19 Oregon Health Sciences University Canaux potassium a basse et moyenne conductance actives par le calcium et leurs utilisations
WO1999025347A2 (fr) * 1997-11-14 1999-05-27 Neurosearch A/S Composes chimiques ayant une activite de blocage des canaux ioniques et servant au traitement de troubles immunitaires
JPH11209302A (ja) * 1998-01-21 1999-08-03 Pola Chem Ind Inc 抗掻痒剤
WO2000034228A1 (fr) * 1998-12-04 2000-06-15 Neurosearch A/S Agents de modulation de canaux ioniques
WO2000033834A1 (fr) * 1998-12-04 2000-06-15 Neurosearch A/S Utilisation de derives d'isatine en tant qu'agents d'activation de canaux ioniques
WO2000034248A1 (fr) * 1998-12-04 2000-06-15 Neurosearch A/S Nouveaux derives de benzimidazolone, de benzoxazolone ou de benzothiazolone agissant comme agents de modulation de canaux ioniques
WO2000037422A2 (fr) * 1998-12-22 2000-06-29 Neurosearch A/S Agents de modulation de canaux ioniques

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CUTHBERT A W ET AL: "Activation of Ca2+- and cAMP-sensitive K+ channels in murine colonic epithelia by 1-ethyl-2-benzimidazolone.", AMERICAN JOURNAL OF PHYSIOLOGY, vol. 277, no. 1 PART 1, July 1999 (1999-07-01), pages C111 - C120, XP002216462, ISSN: 0002-9513 *
KOEGEL HEIDI ET AL: "Expression and biological significance of Ca2+-activated ion channels in human keratinocytes.", FASEB JOURNAL, vol. 15, no. 1, January 2001 (2001-01-01), pages 145 - 154, XP002209209, ISSN: 0892-6638 *
PATENT ABSTRACTS OF JAPAN vol. 1999, no. 13 30 November 1999 (1999-11-30) *

Also Published As

Publication number Publication date
EP1345618A2 (fr) 2003-09-24
WO2002053171A2 (fr) 2002-07-11
ATE291435T1 (de) 2005-04-15
JP2004530642A (ja) 2004-10-07
EP1345618B1 (fr) 2005-03-23
CA2433041A1 (fr) 2002-07-11

Similar Documents

Publication Publication Date Title
PT1091975E (pt) Nova ciclosporina com um perfil de actividade melhorado
WO2002040634A3 (fr) Minireseaux d'expression et leurs utilisations
MXPA01008882A (es) Metodo y sistema para el descubrimiento de cookies y otra informacion del cliente.
BR9815653B1 (pt) produto de carbono modificado, composiÇço de revestimento e composiÇço de tinta.
ME00578A (en) Use of gastrointestinal lipase inhibitors
BR0110979B1 (pt) combinaÇÕes de substÂncias ativas com propriedades inseticidas e acaricidas, processo para sua preparaÇço e aplicaÇço.
AU2001266075A1 (en) Combinations of active ingredients, which exhibit insecticidal and acaricidal properties
WO2000046359A3 (fr) Medicament
WO2002092122A3 (fr) Utilisation d'osteopontine dans le traitement et/ou la prevention de maladies neurologiques
IT1319258B1 (it) Catalizzatore per la idrodeclorurazione del tetracloruro di carbonio acloroformio.
WO2001072125A8 (fr) Combinaisons de principes actifs ayant des proprietes insecticides et acaricides
EE04685B1 (et) Ravimi l„bimiskiirust kontrolliv membraan v?i maatriks
WO2002066500A3 (fr) ANTAGONISTES DE Α4β7-INTEGRINE
WO1995006764A3 (fr) Oligonucleotides ayant une activite de segmentation de l'arn
WO2002055552A3 (fr) Analogues cycliques solubles
WO1999004011A3 (fr) Antigenes du groupe o du vih-1 et leurs utilisations
EP1448582A4 (fr) Interference avec l'activite de la telomerase
WO2002053171A3 (fr) Utilisation de canaux potassiques de conductance intermediaire et de modulateurs pour le diagnostic et le traitement d'affections a activite keratinocytaire perturbee
AU6849198A (en) Neurotrypsin
AP2781A (en) Oxidized proteins, their biological activity, and therapeutic and diagnostic measures, which are derived from the active mechansim, from the use of these porteins or from the inhibition thereof
WO1999050671A3 (fr) Proteine toso comme cible de criblage de medicaments
WO2002056013A3 (fr) Sondes a photoaffinite pour l'oxazolidinone, modes d'utilisation et composes associes
WO2002072883A3 (fr) Support nucleotidique destine au diagnostic et a la therapie de maladies buccales
WO1999016887A3 (fr) Compositions et techniques permettant d'identifier les inhibiteurs de la kinase de la pkb
AU2002250842A1 (en) DNA sequence of the enzyme phospholipase A1 of ciliate tetrahymena, and the use of the same

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2001272669

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2433041

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2002217160

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2002554120

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 2001272669

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 10451805

Country of ref document: US

WWG Wipo information: grant in national office

Ref document number: 2001272669

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载